These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 28043042

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
    Ikeda T, Atarashi H, Inoue H, Uchiyama S, Kitazono T, Yamashita T, Shimizu W, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J, Sugishita N, Shimizu S, Shimokawa H.
    Tohoku J Exp Med; 2016 Dec; 240(4):259-268. PubMed ID: 27904005
    [Abstract] [Full Text] [Related]

  • 3. The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
    Shimokawa H, Yamashita T, Uchiyama S, Kitazono T, Shimizu W, Ikeda T, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J, Sugishita N, Shimizu S, Atarashi H, Inoue H.
    Int J Cardiol; 2018 May 01; 258():126-132. PubMed ID: 29429636
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).
    Suzuki S, Morishima Y, Takita A, Yagi N, Otsuka T, Arita T, Yamashita T.
    Heart Vessels; 2019 Dec 01; 34(12):2011-2020. PubMed ID: 31123819
    [Abstract] [Full Text] [Related]

  • 7. Coagulation Test Interpretation in a Patient Taking Direct Oral Anticoagulant Therapy.
    Sholzberg M, Xu Y.
    JAMA; 2018 Oct 09; 320(14):1485-1486. PubMed ID: 30242329
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
    Barón-Esquivias G, Fernández-Avilés F, Atienza F, Pastor Pueyo P, Toro R, Sanmartín Fernández M.
    Expert Rev Cardiovasc Ther; 2015 Apr 09; 13(4):341-53. PubMed ID: 25797900
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban.
    Nakano Y, Kondo T, Osanai H, Murase Y, Nakashima Y, Asano H, Ajioka M, Sakai K, Inden Y, Murohara T.
    J Cardiol; 2015 Mar 09; 65(3):185-90. PubMed ID: 25192594
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population.
    Kitagawa F, Ishii J, Hiramitsu S, Takahashi H, Okuyama R, Kawai H, Muramatsu T, Harada M, Motoyama S, Naruse H, Matsui S, Sarai M, Hayashi M, Watanabe E, Izawa H, Ozaki Y.
    Heart Vessels; 2017 May 09; 32(5):609-617. PubMed ID: 27796530
    [Abstract] [Full Text] [Related]

  • 15. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
    Horinaka S, Sugawara R, Yonezawa Y, Ishimitsu T.
    Br J Clin Pharmacol; 2018 Jan 09; 84(1):79-87. PubMed ID: 28888219
    [Abstract] [Full Text] [Related]

  • 16. [Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
    Neira V, Corbalán R, Pereira J, Panes O, Garayar B, Aizman A, Llevaneras S, Villarroel L.
    Rev Med Chil; 2016 Sep 09; 144(9):1103-1111. PubMed ID: 28060970
    [Abstract] [Full Text] [Related]

  • 17. Rivaroxaban for Periprocedural Anticoagulation Therapy in Japanese Patients Undergoing Catheter Ablation of Paroxysmal Non-Valvular Atrial Fibrillation.
    Kawabata M, Sasaki T, Maeda S, Shirai Y, Yamauchi Y, Nitta J, Goya M, Hirao K.
    Int Heart J; 2016 Dec 02; 57(6):712-716. PubMed ID: 27818480
    [Abstract] [Full Text] [Related]

  • 18. [Anticoagulation for patients with non-valvular atrial fibrillation].
    Mizoguchi T, Yasaka M.
    Nihon Rinsho; 2016 Apr 02; 74(4):627-33. PubMed ID: 27333751
    [Abstract] [Full Text] [Related]

  • 19. CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban.
    Peacock WF, Tamayo S, Patel M, Sicignano N, Hopf KP, Yuan Z.
    Ann Emerg Med; 2017 May 02; 69(5):541-550.e1. PubMed ID: 27913059
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.